Akeneo Celebrates Excellence in Product Experiences at Unlock 2025 Chicago
Annual PXM Champions Awards ceremony recognizes customers using Akeneo solutions to strengthen product experiences and accelerate growth
CHICAGO, April 10, 2025 /PRNewswire/ -- Akeneo, the Product Experience (PX) Company and leading provider of Product Information Management (PIM) solutions, today announced the winners of the Unlock 2025 PXM Champions Awards. The ceremony took place at the Akeneo Unlock 2025 Chicago event, the most unique and vibrant conference for the global PX community, held on April 8-9. The winners, including Sealed Air Corporation, Steelcase, Tiffany & Co., Giant Tiger Stores Limited, and JC Perreault, discussed their successful PX strategies, sharing best practices and insights into how Akeneo has helped them dramatically improve customer experiences and turn browsers into buyers.
'Each year, we are proud to recognize the PXM Champions who are raising the bar for product experiences and delivering next-generation omnichannel engagement,' said Romain Fouache, Akeneo's Chief Executive Officer. 'Working with Akeneo and our partners, these best-in-class organizations are delivering the rich, contextual and accurate product information customers need to make informed decisions – helping to drive conversions, reduce returns and accelerate bottom-line growth.'
This year's five 2025 PXM Champions Awards were presented to:
Expansion Award: Sealed Air Corporation (Partner: Perficient)
Working with Akeneo and partner Perficient, Sealed Air is able to automate the creation of sell sheets and product data sheets with accurate product data, at scale using branded brochure templates, significantly increasing their efficiency and consistency in marketing collateral production. These improvements have significantly enhanced Sealed Air's market presence and partner satisfaction.
Accelerator Award: Steelcase (Partner: ( O2 Commerce)
As a global leader in office furniture, Steelcase spent countless hours and resources managing product details across regions and ensuring accuracy. Leveraging Akeneo Product Cloud and partnering with O2 Commerce, Steelcase achieved key milestones in efficiency and productivity, including:
67% increased efficiency rate in managing key product details across multi-regional finish records that need to be managed in multiple regions with SDM.
Release hours decreased by 63.61% (from 16.68 to 6.07 per release).
Annual time spent loading supplier data reduced from 33.36 hours to 12.14 hours, a savings of over 62%.
Global Award: Tiffany & Co. (Partner: Valtech)
As Tiffany & Co. sought to launch in new global markets, the focus was on improving product data quality and increasing time to market. Working with Akeneo, Tiffany & Co. created a comprehensive data cleansing process and reduced the amount of product information errors on the website, significantly improving product consistency and accuracy. Tiffany & Co. was also able to scale their business, successfully launching and supporting seven new markets within six months, including the official e-commerce market in South Korea. Tiffany & Co. was able to tailor product information specifically to the Korean market, respecting local cultural and linguistic nuances because of Akeneo's PIM system.
Leadership Award: Giant Tiger Stores Limited (Partner: Sitation)
In fast-paced consumer retail segments, speed and keeping pace with change are key factors to success. With Akeneo's centralized platform, Giant Tiger Stores' assets are stored with meta tags and organized into searchable families, allowing the team to find images faster and reduce preparation time for new product launches. This enables faster time-to-market and allows teams to focus on creative, strategic efforts rather than tedious searches. The success has been so widespread, cross-departmental interest in Akeneo has grown significantly, as teams from other areas of the business have been inspired by marketing's success, and are exploring how Akeneo can streamline their processes, too.
Experience Award: JC Perreault (Partner: Valtech)
Maintaining a consistent, accurate product experience across eCommerce channels can be challenging, especially as new products come to market quickly and product teams need to keep up. Partnering with Akeneo and Valtech, JC Perreault went from launching new products in two weeks, to now only 24 hours. By centralizing and structuring product information more effectively, Akeneo significantly improved product data quality, reduced time-to-market, and increased the online product range by 4X.
Global Ambassador Award: Andrew Cofield
Andrew's commitment to excellence in product experiences extends beyond external storytelling. Internally, he has championed Akeneo's value through the creation of dynamic and engaging sizzle reels, which have effectively demystified the complexities of PIM, enabling his team to grasp its significance and embrace its capabilities. His passion for Akeneo is palpable; he truly breathes the purple fire. His enthusiasm and dedication have inspired others to explore and leverage the full potential of Akeneo Product Cloud. As a member of Akeneo's Customer Advisory Board and beyond this role, Andrew's contributions have enriched our community, fostering a deeper understanding and appreciation for the power of effective product information.
This year's Unlock 2025 Chicago event builds on the momentum of the Unlock 2025 Tour, with prior events taking place in Paris, London and Düsseldorf this year. For those unable to attend the Akeneo Unlock in-person events, tune into the Unlock: Digital, taking place the week of May 5th.
Attendees of the annual PX conference will be better positioned to embrace modern omnichannel strategies, learn how to leverage new tools and harness AI strategies, and unlock the roadmap to delivering dynamic, engaging shopping experiences for every customer, everywhere they shop. Learn more about Akeneo's solutions: Akeneo Product Cloud.
About Akeneo
Akeneo is the product experience (PX) company and global leader in Product Information Management (PIM); creating a world where every product interaction is an experience that guides consumers and professionals to the best purchase, anytime, anywhere. Akeneo empowers business leaders with software, education, and an engaged community all focused on the practice of product experience management.
Leading global brands, manufacturers, distributors, and retailers, including Chico's, CarParts.com, TaylorMade Golf, Rail Europe, Kering, and more trust Akeneo to scale and customize their omnichannel commerce initiatives. Using Akeneo's intelligent Product Cloud, companies can create elevated product experiences with user-friendly and AI-powered product data enrichment, management, syndication, and supplier data onboarding; as well as a comprehensive app marketplace and partner network to meet business and buyer needs. For more information: www.akeneo.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
JPMorgan Lifts 2025 Muni-Bond Sales Forecast to $560 Billion
(Bloomberg) -- JPMorgan Chase & Co. raised its forecast for 2025 municipal bond issuance by 14% as state and local governments step up borrowing efforts. Next Stop: Rancho Cucamonga! Where Public Transit Systems Are Bouncing Back Around the World Trump Said He Fired the National Portrait Gallery Director. She's Still There. US Housing Agency Vulnerable to Fraud After DOGE Cuts, Documents Warn Senator Calls for Closing Troubled ICE Detention Facility in New Mexico The bank's muni strategists led by Peter DeGroot lifted their full-year issuance prediction to $560 billion from $490 billion, according to a research report published Friday. Almost all of the sales, $510 billion, is expected to be tax-exempt — up from an earlier projection of $450 billion and about 30% higher than the trailing five-year average. The revision comes 'in advance of potential policy limiting the authorization to issue tax-exempts in certain sectors of the market, pent up need for capital, and the cumulative impact of inflation on funding needs across the market,' the strategists wrote in the report. JPMorgan is the third-largest underwriter of muni bonds so far this year, according to data compiled by Bloomberg. States and local governments sold $20 billion of debt last week, the most since the end of 2017, according to data compiled by Bloomberg, as pandemic-era stimulus aid wanes and inflation drives up the cost of projects. So far this year, California has issued the most muni bonds, followed by New York, according to the report. States such as Indiana, Nebraska, Ohio, Colorado and Connecticut that tend to issue bonds at a lower volume saw increases in debt sales of more than 80%. While the higher education, airport and health care sectors saw an increased pace of muni-bond sales in the first half of the year, JPMorgan strategists expect a slowdown, 'assuming the GOP's reconciliation bill continues to leave the tax-exemption off the list of budget cuts.' The industry has been on edge with the possibility of muni-bonds losing their tax-exempt status as lawmakers look to raise revenue to offset the costs of the Trump administration's tax cuts. --With assistance from Amanda Albright. The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again New Grads Join Worst Entry-Level Job Market in Years What America's Pizza Economy Is Telling Us About the Real One America Cast Itself as the World's Moral Leader. Not Anymore ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Christie & Co appointed to list Banchory Lodge Hotel for $4.74m
Business property adviser Christie & Co is facilitating the sale of Banchory Lodge Hotel, a hospitality destination in Royal Deeside, Aberdeenshire, Scotland. The property, which is on the market for £3.5m ($4.74m), encompasses 28 boutique ensuite bedrooms, each featuring contemporary Scottish interiors. Banchory Lodge Hotel is nestled within 7.5 acres of private grounds and offers a private lodge that provides six en-suite bedrooms, a lounge, and a dining room. This space is particularly suited for private parties interested in golfing activities that require exclusivity. Over the years, the Georgian estate has been maintained and updated to provide a destination for both leisure and corporate guests. The property has also established itself as a location for weddings and events. The hotel's amenities include a restaurant and bar, a 'sitooterie' with a large, covered terrace, cabins, and an outdoor kitchen. It caters to a diverse clientele, from those engaging in outdoor activities such as fishing, golfing, and cycling, to guests exploring the landscapes of Royal Deeside. Christie & Co Hotels director Gary Witham is overseeing the sale process. Gary Witham said: 'Banchory Lodge offers a modern, stylish hotel business with many different business strands. The appeal of the beautiful riverside grounds and 'sitooterie' makes this a must-visit for the region.' The announcement of Banchory Lodge Hotel's sale follows Christie & Co's recent facilitation of the Bournemouth West Cliff Hotel & Spa sale, highlighting the company's active role in the UK's hotel property market. "Christie & Co appointed to list Banchory Lodge Hotel for $4.74m" was originally created and published by Hotel Management Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
6 hours ago
- Yahoo
Merck claims study success with PCSK9 cholesterol pill
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. An experimental cholesterol-lowering pill from Merck & Co. succeeded in a pair of late-stage studies, the company said Monday. In one study, Merck's drug, enlicitide, was tested against a placebo in people already taking statins and who have either an inherited condition that causes high cholesterol or are at risk of atherosclerosis. The second trial evaluated enlicitide against other oral therapies, such as ezetimibe, in people on statins and with abnormally high levels of fats in the blood. Merck didn't provide specifics, but said in both cases enlicitide met all of its study objectives and demonstrated 'statistically significant and clinically meaningful reductions' in LDL-C, or 'bad' cholesterol, without any important differences in the number of adverse events. Details will be presented at a future medical meeting. Company shares climbed 2% in early trading Monday. A decade ago, the Food and Drug Administration approved a pair of injectable treatments that could dramatically lower cholesterol in people with heart disease. The drugs, known as PCSK9 inhibitors for the cholesterol-regulating protein they target, were hailed as medical breakthroughs and billed as multibillion-dollar sellers. Instead, their developers struggled to convince payers and physicians of their worth. Sales totals, until recently, have largely disappointed. Merck believes it will have better luck with enlicitide, which could be the first oral medication that blocks PCSK9. The company has bet heavily on its future, enrolling about 17,000 participants across several late-stage studies. And it's counting on enlicitide to become one of the products that can help it grow sales once the patents protecting Keytruda, its dominant cancer immunotherapy, expire later this decade. Questions about its post-Keytruda future have spurred a 40% share slide over the last year and heightened pressure on its next prospects to succeed. The company, for its part, has spoken boldly about enlicitide's promise. Research chief Dean Li has described it as likely becoming the first of its kind available, the 'most effective' cholesterol-lowering pill medicine on the market, and the foundation for future drug combinations. Enlicitide should also be able to sidestep the reimbursement issues long weighing down sales of PCSK9 blockers, CEO Robert Davis said during a presentation in January. Though the drug is a so-called macrocyclic peptide and thus more complicated to make than traditional small molecule pills, Merck has invested significantly in production and believes it can manufacture enlicitide at a low cost. That could help the company 'price it in a way that won't create the excess challenges' others have had and obtain a 'competitive advantage,' Davis said. Still, there is a large collection of branded and generic cholesterol drugs available, as well as multiple newer medicines in advanced testing. AstraZeneca, for one, has a PCSK9 pill in development that some analysts believe to be a meaningful threat to Merck's program. While there are 'early signs' Merck's drug might be more effective, AstraZeneca's could be 'more tolerable and easier to administer,' Leerink Partners analyst Daina Graybosch wrote in April. The size of enlicitide's effects in Phase 3 testing, then, will be closely scrutinized. In Phase 2 trials, a variety of enlicitide doses lowered LDL levels by up to 60% after eight weeks of treatment. One of the Phase 3 studies Merck reported on Monday tested cholesterol levels after 24 weeks, and there is typically a 'degradation in efficacy' when companies move a drug into larger, longer trials, wrote Jefferies analyst Dennis Ding. Ding also speculated that drug adherence could be lower in Merck's studies, as food intake disrupts enlicitide effectiveness. 'The magnitude of benefit will be key to watch,' he wrote.
